Hillary Clinton Spreads Rachel Maddow's Story of Ending Lunch Breaks for Child Workers
Poll Shows the Democrat Base Is Unmarried Women
Squatter in Detroit Explains How She's Put a Lot of Work and Money...
WUT? Days After Gutting Title IX, Biden Says Trump Has Taken Women’s Rights...
In an Example of a Complete Lack of Self Awareness, Chris Christie...
New York Magazine Profiles Will Stancil, 'One of Politics Twitter's Most Inescapable Power...
DEADLY DEI: UCLA Med School Docs Say 'Obesity' Is a Slur, Weight Loss...
Biden Simp Harry Sisson Says Biden's Ban on TikTok Will Hurt Black-Owned Businesses
Prosecutors in Trump’s New York Trial Prove Their Witness is a Lying 'Pecker'...
Rep. AOC Wants to Know Where Are the Journalists on the Mass Graves...
'Redacting Reality': WH Transcript Runs Cover After Joe 'Ron Burgundy' Biden's Teleprompte...
FOX News: President Biden Forgives Violinist's $250,000 Student Loan
Paging Dr. Freud: Biden's Slip of the Tongue Is the MOST Honest Thing...
Try Not to Roll Your Eyes at the United Nations' New Ally in...
NYU Protester Describes the Ordeal of Her Arrest, Assumes Cops Are White Supremacists

Christina Pushaw busts the AP for acknowledging a COVID treatment fact they shamed Ron DeSantis for pointing out just a few months ago

Yesterday, the Associated Press’ Matthew Perrone reported a possible setback for a couple of COVID19 treatments, including Regeneron.

Advertisement

More from the AP:

As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.

But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.

The fact that Regeneron may not be as effective against the omicron variant as it’s been against others is noteworthy enough. But Gov. Ron DeSantis’ press secretary Christina Pushaw finds something else noteworthy, too:

Things sure have changed, haven’t they? Recall this past August, when the AP was entertaining the idea that DeSantis was promoting sketchy Regeneron in some kind of quid pro quo scheme because one of his top donors had invested money in Regeneron, making DeSantis shady AF and not to be trusted.

Advertisement

Pushaw called out the AP then.

Just like she’s calling out the AP now.

We’ve got whiplash.

And Pushaw’s got one last question for the AP:

Join the conversation as a VIP Member

Recommended

Trending on Twitchy Videos

Advertisement
Advertisement
Advertisement